TY - JOUR
T1 - 14-3-3σ expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients
AU - Perathoner, Alexander
AU - Pirkebner, Daniela
AU - Brandacher, Gerald
AU - Spizzo, Gilbert
AU - Stadlmann, Sylvia
AU - Obrist, Peter
AU - Margreiter, Raimund
AU - Amberger, Albert
PY - 2005/5/1
Y1 - 2005/5/1
N2 - Purpose: 14-3-3σ is an intracellular, dimeric, phosphoserine binding protein that is expressed in epithelial cells and involved in cancer development. In this study was examined the expression of 14-3-3σ and evaluated its clinical significance in colorectal carcinoma. Experimental Design: Expression of 14-3-3σ was analyzed by Western blot in nine colorectal carcinoma cell lines, eight paired colorectal carcinoma tissues, and normal mucosas. Immunohistochemistry was used to evaluate expression of 14-3-3σ in tissues of 121 colorectal carcinoma patients and to correlate it with clinical parameters. Results: Western blot analysis of colorectal carcinoma cell lines and tissues revealed strong 14-3-3σ expression in four of eight cell lines and 14-3-3σ overexpression in carcinoma compared with normal mucosa in six of eight colorectal carcinoma tissue pairs. Immunohistochemical analysis revealed 14-3-3σ overexpression in 38.8% of colorectal carcinoma samples. Furthermore, highly positive immunoreactivity was significantly correlated with tumor differentiation (P < 0.001) and pT stage (P < 0.003). In Kaplan-Meier analysis, 14-3-3σ overexpression was associated with a significantly decreased survival time compared with negatively stained or low stained cases (P < 0.0096). In multiveriate regresion analysis, 14-3-3σ expression emerged as a significant independent parameter (P < 0.037). Conclusions: These results provide evidence that 14-3-3σ expression increases during carcinoma progression in a subset of colorectal carcinoma. The overexpression of this antigen identifies patients at high risk. It is tempting to suggest that 14-3-3σ overexpression either promotes tumor proliferation and/or prevents apoptotic signal transduction in colorectal carcinomas. Thus, targeting 14-3-3σ might be a new therapeutic strategy in colorectoral carcinoma.
AB - Purpose: 14-3-3σ is an intracellular, dimeric, phosphoserine binding protein that is expressed in epithelial cells and involved in cancer development. In this study was examined the expression of 14-3-3σ and evaluated its clinical significance in colorectal carcinoma. Experimental Design: Expression of 14-3-3σ was analyzed by Western blot in nine colorectal carcinoma cell lines, eight paired colorectal carcinoma tissues, and normal mucosas. Immunohistochemistry was used to evaluate expression of 14-3-3σ in tissues of 121 colorectal carcinoma patients and to correlate it with clinical parameters. Results: Western blot analysis of colorectal carcinoma cell lines and tissues revealed strong 14-3-3σ expression in four of eight cell lines and 14-3-3σ overexpression in carcinoma compared with normal mucosa in six of eight colorectal carcinoma tissue pairs. Immunohistochemical analysis revealed 14-3-3σ overexpression in 38.8% of colorectal carcinoma samples. Furthermore, highly positive immunoreactivity was significantly correlated with tumor differentiation (P < 0.001) and pT stage (P < 0.003). In Kaplan-Meier analysis, 14-3-3σ overexpression was associated with a significantly decreased survival time compared with negatively stained or low stained cases (P < 0.0096). In multiveriate regresion analysis, 14-3-3σ expression emerged as a significant independent parameter (P < 0.037). Conclusions: These results provide evidence that 14-3-3σ expression increases during carcinoma progression in a subset of colorectal carcinoma. The overexpression of this antigen identifies patients at high risk. It is tempting to suggest that 14-3-3σ overexpression either promotes tumor proliferation and/or prevents apoptotic signal transduction in colorectal carcinomas. Thus, targeting 14-3-3σ might be a new therapeutic strategy in colorectoral carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=18244386009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244386009&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-04-2207
DO - 10.1158/1078-0432.CCR-04-2207
M3 - Article
C2 - 15867223
AN - SCOPUS:18244386009
SN - 1078-0432
VL - 11
SP - 3274
EP - 3279
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 9
ER -